The deoxycytidine analog 5-aza-2'-deoxycytidine (5-azadCyd) has been widely used as a DNA methylation inhibitor to experimentally induce gene expression and cellular differentiation. Prior to the availability of mutant mice with altered DNA methyltransferase levels, treatment of cells with drugs has been the only means to experimentally manipulate the level of genomic DNA methylation in mammalian cells. Substitution ofDNA with 5-azadCyd leads to covalent trapping of the enzyme, thereby depleting the cells of enzyme activity and resulting in DNA demethylation. 5-AzadCyd or 5-azacytidine treatment causes multiple changes in treated cells, including activation of silent genes, decondensation of chromatin, and induction ofcellular differentiation, all of which are believed to be consequences of drug-induced demethylation. 5-AzadCyd is highly toxic in cultured cells and animals and is utilized as a potent antitumor agent for treatment of certain human cancers. It has been postulated that the toxicity of the drug in mammalian cells is also due to its inhibition of DNA methylation. The chemistry of the methylation reaction is consistent, however, with an alternative mechanism: the cytotoxic effect of 5-azadCyd may be directly mediated through the covalent binding of DNA methyltransferase to 5-azadCydsubstituted DNA. We have tested this possibility by using embryonic stem cells and mice with reduced levels of DNA methyltransferase due to a targeted mutation ofthe gene. When exposed to 5-azadCyd mutant embryonic stem cells or embryos were sigfntly more resistant to the toxic effects of the drug than wild-type cells and embryos, respectively. These results strongly suggest that the cellular DNA methyltransferase itself, rather than the secondary demethylation of genomic DNA, is the primary mediator of5-azadCyd cytotoxicity. In light ofour results, some conclusions from previous studies using 5-azadCyd in order to experimentally manipulate cellular methylation levels may have to be reassessed. Also, our data make clear predictions for cancer treatment: tumor cells with elevated DNA methyltransferase levels would be expected to be susceptible to treatment with 5-azadCyd, whereas tumors with re-
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5-Aza-2'-deoxycytidine (5-azadCyd) is widely used as a DNA methylation inhibitor to induce gene expression and cellular differentiation. To exert its biological effects, the drug must be incorporated into the DNA (1). 5-AzadCyd-substituted DNA or DNA substituted with the ribose analog 5-azaCyd forms covalent adducts with cellular DNA methyltransferase (MTase), thereby depleting the cells of enzyme activity and causing demethylation of genomic DNA as a secondary consequence (1, 2) . Treatment with 5-azadCyd or 5-azaCyd also causes various other changes in cells, including activation of silent genes (3, 4) , decondensation of chromatin (5), and alteration of DNA replication timing (6) , all of which are believed to be consequences of drug-induced demethylation.
In addition to causing multiple changes in cell physiology, 5-azaCyd and 5-azadCyd are highly toxic in cultured cells (7, 8) and animals (9, 10) . For this reason, 5-azadCyd is utilized as a potent anticancer agent for treatment of certain leukemias, such as acute myeloid leukemia, and myelodysplastic syndromes (11) . Phase I and II trials have been conducted with different types of cancer, including colorectal cancer, head and neck cancers, renal carcinomas, and malignant melanomas (12, 13) . The toxicity of the drug in mammalian cells has been attributed to its inhibitory effect on DNA methylation (14) . It has been postulated that the antitumor effect of the drug might be due to the transcriptional activation ofdifferentiation genes leading to terminal differentiation of undifferentiated cancer cells (15) (16) (17) .
An alternative mechanism of drug-induced cytotoxicity is suggested by the chemistry of the methylation reaction. The methylation of cytosine involves the covalent binding of the MTase to the cytosine residue through a nucleophilic attack of a cysteine thiolate at the C-6 position of the cytosine ring. The covalent binding of the enzyme at C-6 allows for a nucleophilic attack at C-5 by the methyl group of the S-adenosylmethionine methyl donor and the subsequent transfer of a methyl group to C-5. The resulting intermediate is resolved by 1-elimination of the enzyme at C-6 with abstraction of the hydrogen from C-5 (18-20) (Fig. 1A) . When dCyd is replaced by 5-azadCyd in the DNA, C-6 of the cytosine residue reacts with the cysteine thiolate of the enzyme to form a 5,6-dihydropyrimidine adduct as described above. In contrast to normal DNA, however, the enzyme remains covalently bound under physiological conditions and cannot be released from the 5-azadCyd-substituted DNA, thus decreasing the cellular concentration of MTase (1, 2, 21) (Fig.  1B) . This leads subsequently to demethylation of genomic DNA.
In this study we sought to establish the mechanism of 5-azadCyd toxicity in cells and animals. If demethylation of genomic DNA is the primary cause of drug toxicity, as conventionally assumed (16, 17) , cells expressing reduced levels of MTase should be more sensitive to 5-azadCyd than normal cells. In contrast, if covalent binding of the enzyme to 5-azadCyd-substituted DNA rather than genomic DNA demethylation was the primary mechanism of drug-induced toxicity, mutant cells expressing lower levels of MTase should be more resistant to 5-azadCyd. To distinguish between these two possibilities, we compared the drug sensitivity of mutant cells or mice expressing reduced levels of (18, 19) . This intermediate is generated by nucleophilic attack on the C-6 position of cytosine by a cysteine residue of the enzyme. The activated C-5 of cytosine then attacks the methyl group ofS-adenosylmethionine which subsequently is added to C-5, followed by deprotonation ofC-5 and release ofthe enzyme by P-elimination.
(B) Proposed reaction mechanism when 2'-deoxycytidine is replaced by the analog 5-azadCyd. The MTase is trapped in an inactivating intermediate (21) .
MTase due to a targeted mutation of the gene with that of their wild-type counterparts.
MATERIALS AND METHODS
Embryonic Stem (ES) Cell Culture and Drug Treatment. ES cells were cultured essentially as described (22 24 hr, starting at 12 hr after seeding with various concentrations of 5-azadCyd. Cultures were passaged once at day 5 after seeding and DNA was prepared (23) at day 9 after four rounds of treatment. Embryonic fibroblasts were seeded into T25 flasks and treated with 5-azadCyd. The 5-azadCyd-containing medium was changed every day for 4 days, cells were passaged when confluent, and DNA was prepared at day 5.
Southern Blot Analysis. Purified DNA was digested with restriction endonuclease, fractionated by electrophoresis through 0.8 or 1.0% agarose gels, denatured in 0.5 M NaOH/ 1.5 M NaCl for 30 (22) . Mice heterozygous for the mutation are normal, whereas homozygous mutant embryos die at midgestation. Mutant cells and mice were used to investigate whether demethylation was the primary cause of 5-azadCyd-mediated cytotoxicity.
To measure the sensitivity to the toxic effect of the drug, ES cells were exposed to various concentrations of 5-azadCyd 1 day after seeding. The drug was removed after 24 hr and the cells were grown in normal medium for 9 days before colonies were counted. The number of surviving wild-type ES cell colonies declined rapidly with increasing concentrations of 5-azadCyd, with 50%o survival at 0.05 ,uM drug concentration (Fig. 2) . Exposure of heterozygous MTase mutant ES cells to the drug resulted in a slightly increased survival. ES cells homozygous for the mutation were substantially more resistant to the drug than the normal control cells, with 50% survival at a 10-fold higher concentration (0.5 ,uM 5-azadCyd).
To assess whether repeated exposure to low concentrations of the drug would lead to a growth advantage of mutant cells with reduced levels of MTase over normal cells, an equal number of wild-type and heterozygous cells or of wild-type and homozygous ES cells were seeded into the same dish. The mixed cultures were treated every 2 days with 5-azadCyd, DNA was prepared after a total of 9 days (four treatments), and Southern blot analysis was used to quantify the ratio of mutant to wild-type cells. In this analysis, a 5.3-kb band corresponding to the wild-type MTase allele is found in wild-type ES cells, two bands of 5.3 kb and 6.1 kb are found in heterozygous cells, and a single band at 6.1 kb corresponding to the mutant allele (22) treated with low concentrations of 5-azadCyd (Fig. 3) (9) . It was of interest to investigate whether embryos heterozygous for the MTase mutation would be more resistant to the toxic effects of5-azadCyd than wild-type embryos as would be expected from the observations described above. Wild-type females were mated with heterozygous MTase mutant males and the pregnant females were injected with a single dose of 5-azadCyd at day 14 of gestation and allowed to deliver their pups. Offspring were genotyped by PCR analysis. As expected, -50%o of the offspring from females injected with saline were wild type, the rest being heterozygous for the mutation ( Table 1) . Injection of 5-azadCyd resulted in a lower fraction of wildtype offspring at birth, which further decreased in a dosedependent manner when the mice were genotyped at weaning. The frequency of wild-type weanlings from females injected with 200 and 300 1AM 5-azadCyd was 30% and 22%, respectively. Significantly, of a total of 24 wild-type mice derived from drug-injected females, 18 were severely sick, 14 being runts and 4 displaying severe hair loss and skin ulceration. In contrast, only 3 of a total of 64 heterozygous litter mates were visibly affected, whereas the remainder were apparently healthy and of normal weight. Fig. 4 shows a typical example of offspring from a drug-injected mother, the wild-type animal being runted and one-third the size of the normal-weight heterozygous littermate. We conclude that MTase mutant embryos, like mutant ES cells, are significantly more resistant to the deleterious effects of 5-azadCyd. 
DISCUSSION
The role ofDNA methylation in gene expression has been the subject of intense investigations over the last two decades. Important tools for these studies have been the cytosine analogs 5-azaCyd and 5-azadCyd, which allow experimental reduction of the level of DNA methylation; only recently have genetic approaches to the study of DNA methylation become feasible, with the generation of MTase mutations in plants (25) , Neurospora (26), and mice (22) . In fact, prior to the generation of mice with a targeted mutation of the MTase gene, treatment of cells with these drugs has been.the only available means to experimentally cause demethylation of genomic DNA in mammalian cells, and a large body of work is based on experiments using drug-induced DNA hypomethylation in cultured cells. The principal conclusions from these studies have been that demethylation ofDNA results in activation of silent genes, including reactivation of the inactive X chromosome (3, 4) , in the change of DNA replication timing (6) , and in decondensation of centromeric chromatin (5). The second major consequence of treating cells with 5-azadCyd is cytotoxicity. However, the relation between cytotoxicity and drug-induced DNA demethylation has not been resolved in previous experiments.
Importantly, 5-azadCyd is clinically used as an anticancer agent which is particularly effective for treatment of leukemias (11, 17) . In contrast to our present understanding of the mechanisms of 5-azadCyd-mediated gene activation, little is known about the mechanism of drug-induced cytotoxicity or development of drug resistance by tumor cells. While all the In light of our results it appears important to reevaluate previous drug studies to assess whether the observed cellular alterations were caused by DNA demethylation as widely assumed rather than by other effects due to the binding of MTase to 5-azadCyd-substituted DNA. We note that experiments using 5-azadCyd as a means to induce demethylation may lead to different conclusions regarding the role of methylation in gene expression than the genetic approach. For example, it has been reported that 5-azadCyd activates the imprinted (inactive) Igf2 allele in cultured cells (35) as well as embryos (27) , suggesting that methylation suppresses Igf2 transcription. In contrast, we have shown (24) that embryos homozygous for the MTase mutation inactivate the active rather than activate the inactive Igf2 allele, leading to the opposite conclusion.
The role of DNA methylation patterns in the genesis of cancer is controversial (36) . Decreased 5-methylcytosine content was found in several tumors (28, 30) and demethylation of specific genes has been associated with colon and lung cancer (29) , whereas in similar tumors hypermethylation of genes and an increase of MTase activity were reported by other investigators (31, 32) . More recently, overexpression of MTase in 3T3 cells has been shown to result in cellular transformation (33) . Our results predict that a tumor with increased MTase activity should be more sensitive to the anticancer activity of 5-azadCyd and that the treatment may, in effect, select for tumor variants with decreased enzyme expression which would, as a consequence, be resistant to the drug. The availability of a defined animal system which allows genetic manipulation of MTase levels should help to Proc. Natl. Acad. Sci. USA 91 (1994) Proc. Natl. Acad. Sci. USA 91 (1994) 11801 define the mechanisms of the drug's antitumor activity as well as the molecular parameters of tumor resistance.
